Alector Q1 net loss $36.1M ($0.38/share); cash runway through 2026

Alector, Inc.

2024-Q1 EPS reported -$0.38 revenue$15,900,000

Q1 net loss $36.1M ($0.38/share) vs $45.9M ($0.55) in Q1 2023.
Collaboration revenue $15.9M, roughly flat vs $16.5M year ago.
Cash, equivalents & investments $562.1M; expects runway through 2026.
INVOKE-2 Phase 2 TREM2 data for early Alzheimer's expected Q4 2024; INFRONT-3 Phase 3 latozinemab fully enrolled.
Neil Berkley named CBO; Errol De Souza and Mark Altmeyer join Board.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Alector, Inc. reported financial results for First Quarter 2024.

Period: First Quarter 2024
Result: reported results

Exact text from the filing

Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today reported first quarter 2024 financial results and recent portfolio and business updates.

View on SEC.gov

708 earnings releases filed in the last 30 days. Browse all earnings releases →

Alector, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-24-055652

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.